Ann Dermatol.  2015 Aug;27(4):355-363. 10.5021/ad.2015.27.4.355.

Personalized Immunomodulatory Therapy for Atopic Dermatitis: An Allergist's View

• Nahm DH

• KMID: 2171489
• DOI: http://doi.org/10.5021/ad.2015.27.4.355

Abstract

The current standard medical therapy for atopic dermatitis (AD) mainly focuses on symptomatic relief by controlling skin inflammation with topical corticosteroids and/or topical calcineurin inhibitors. However, the clinical efficacy of pharmacological therapy is often disappointing to both patients and physicians. The terminology of AD contains a historical meaning of eczematous dermatitis caused by hypersensitivity reaction to environmental inhalant or food allergen. Complex interrelationships among genetic abnormalities, environmental triggers, skin barrier defects, and immune dysfunction resulting in a vicious domino-circle seem to be involved in the development and maintenance of AD. In the viewpoint of AD as an allergic disease, complete avoidance of clinically relevant allergen or induction of specific immune tolerance through administrations of allergen (allergen immunotherapy) can provide clinical remission by breaking the vicious domino-circle maintaining a chronic disease state. In recent clinical studies, monoclonal antibodies including the anti-interleukin-4 receptor antibody and anti-B cell antibody induced significant clinical improvements in patients with AD. The detailed characteristics of immune dysfunction are heterogeneous among patients with AD. Therefore, a personalized combination of immunomodulatory therapies to reduce hypersensitivity (allergen immunotherapy) and correct immune dysfunction (monoclonal antibody therapy) could be a reasonable therapeutic approach for patients with AD. Future immunomodulatory therapies for AD should be developed to achieve long-term treatment-free clinical remission by induction of immune tolerance.

Keyword

Atopic dermatitis; Hypersensitivity; Immunomodulation; Allergens; Therapeutics

MeSH Terms

Adrenal Cortex Hormones
Allergens
Antibodies, Monoclonal
Calcineurin
Chronic Disease
Dermatitis, Atopic*
Eczema
Humans
Hypersensitivity
Immune Tolerance
Immunomodulation*
Inflammation
Skin
Adrenal Cortex Hormones
Allergens
Antibodies, Monoclonal
Calcineurin

Figure

• 

  Fig. 1 One-way vertical flow pathogenesis model of atopic dermatitis. This vertical model suggests that (1) environmental toxicants (e.g., volatile inorganic chemicals, air pollution, and food additives) induce immune dysfunction and hypersensitivity in genetically susceptible human subjects by decreasing the threshold for developing hypersensitivity reaction to environmental allergens and irritants; and (2) exposure to the allergens and/or irritants induces hypersensitivity reaction, chronic skin inflammation, skin barrier defect, and clinical manifestations of atopic dermatitis (pruritus and eczema). In this model, multiple modalities could be introduced to block multiple elements in the pathogenetic pathway for the treatment of atopic dermatitis. In addition, blocking the upper stream of the pathogenetic pathway of this model might be a more effective and fundamental therapeutic approach than blocking the lower stream of the pathogenetic pathway.

• 

  Fig. 2 "Domino theory". A vicious domino-circle formed from negative interactions among multiple pathogenetic elements is essential for the development and maintenance of atopic dermatitis, and if one of the pathogenetic elements (e.g., environmental triggers, immune dysfunction, skin inflammation, or skin barrier defects) can be sufficiently controlled to break the vicious domino-circle, then clinical remission of atopic dermatitis could be possible.

Reference

1. Akdis CA, Akdis M, Bieber T, Bindslev-Jensen C, Boguniewicz M, Eigenmann P, et al. European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol. 2006; 118:152–169.

2. Novak N, Bieber T, Leung DY. Immune mechanisms leading to atopic dermatitis. J Allergy Clin Immunol. 2003; 112:6 Suppl. S128–S139.

3. Bieber T. Atopic dermatitis. Ann Dermatol. 2010; 22:125–137.

4. Beck LA, Thaçi D, Hamilton JD, Graham NM, Bieber T, Rocklin R, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014; 371:130–139.

5. Simon D, Hösli S, Kostylina G, Yawalkar N, Simon HU. Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol. 2008; 121:122–128.

6. Krathen RA, Hsu S. Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol. 2005; 53:338–340.

7. Takiguchi R, Tofte S, Simpson B, Harper E, Blauvelt A, Hanifin J, et al. Efalizumab for severe atopic dermatitis: a pilot study in adults. J Am Acad Dermatol. 2007; 56:222–227.

8. Coca AF, Cooke RA. On the classification of the phenomena of hypersensitiveness. J Immunol. 1923; 8:163–182.

9. Sulzberger MB. Historical notes on atopic dermatitis: its names and nature. Semin Dermatol. 1983; 2:1–4.

10. Furue M, Chiba T, Takeuchi S. Current status of atopic dermatitis in Japan. Asia Pac Allergy. 2011; 1:64–72.

11. Halbert AR, Weston WL, Morelli JG. Atopic dermatitis: is it an allergic disease. J Am Acad Dermatol. 1995; 33:1008–1018.

12. Lee HJ, Lee SH. Epidermal permeability barrier defects and barrier repair therapy in atopic dermatitis. Allergy Asthma Immunol Res. 2014; 6:276–287.

13. Leung DY. New insights into atopic dermatitis: role of skin barrier and immune dysregulation. Allergol Int. 2013; 62:151–161.

14. Raimer SS. Managing pediatric atopic dermatitis. . Clin Pediatr (Phila). 2000; 39:1–14.

15. Carroll CL, Balkrishnan R, Feldman SR, Fleischer AB Jr, Manuel JC. The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr Dermatol. 2005; 22:192–199.

16. Sanda T, Yasue T, Oohashi M, Yasue A. Effectiveness of house dust-mite allergen avoidance through clean room therapy in patients with atopic dermatitis. J Allergy Clin Immunol. 1992; 89:653–657.

17. Werfel T, Breuer K, Ruéff F, Przybilla B, Worm M, Grewe M, et al. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study. Allergy. 2006; 61:202–205.

18. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol. 1998; 102:558–562.

19. Bae JM, Choi YY, Park CO, Chung KY, Lee KH. Efficacy of allergen-specific immunotherapy for atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol. 2013; 132:110–117.

20. Novak N, Simon D. Atopic dermatitis-from new pathophysiologic insights to individualized therapy. Allergy. 2011; 66:830–839.

21. Genuis SJ. Sensitivity-related illness: the escalating pandemic of allergy, food intolerance and chemical sensitivity. Sci Total Environ. 2010; 408:6047–6061.

22. Lee JH, Lee HS, Park MR, Lee SW, Kim EH, Cho JB, et al. Relationship between indoor air pollutant levels and residential environment in children with atopic dermatitis. Allergy Asthma Immunol Res. 2014; 6:517–524.

23. Darsow U, Laifaoui J, Kerschenlohr K, Wollenberg A, Przybilla B, Wüthrich B, et al. The prevalence of positive reactions in the atopy patch test with aeroallergens and food allergens in subjects with atopic eczema: a European multicenter study. Allergy. 2004; 59:1318–1325.

24. Tupker RA, De Monchy JG, Coenraads PJ, Homan A, van der Meer JB. Induction of atopic dermatitis by inhalation of house dust mite. J Allergy Clin Immunol. 1996; 97:1064–1070.

25. Tan BB, Weald D, Strickland I, Friedmann PS. Double-blind controlled trial of effect of housedust-mite allergen avoidance on atopic dermatitis. Lancet. 1996; 347:15–18.

26. Hua TC, Hwang CY, Chen YJ, Chu SY, Chen CC, Lee DD, et al. The natural course of early-onset atopic dermatitis in Taiwan: a population-based cohort study. Br J Dermatol. 2014; 170:130–135.

27. Johnson EE, Irons JS, Patterson R, Roberts M. Serum IgE concentration in atopic dermatitis. Relationship to severity of disease and presence of atopic respiratory disease. J Allergy Clin Immunol. 1974; 54:94–99.

28. Zheng T, Yu J, Oh MH, Zhu Z. The atopic march: progression from atopic dermatitis to allergic rhinitis and asthma. Allergy Asthma Immunol Res. 2011; 3:67–73.

29. Schmitt J, Schmitt N, Meurer M. Cyclosporin in the treatment of patients with atopic eczema-a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2007; 21:606–619.

30. Weatherhead SC, Wahie S, Reynolds NJ, Meggitt SJ. An open-label, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczema. Br J Dermatol. 2007; 156:346–351.

31. Kasperkiewicz M, Schmidt E, Frambach Y, Rose C, Meier M, Nitschke M, et al. Improvement of treatment-refractory atopic dermatitis by immunoadsorption: a pilot study. J Allergy Clin Immunol. 2011; 127:267–270.

32. Gustafsson D, Sjöberg O, Foucard T. Sensitization to food and airborne allergens in children with atopic dermatitis followed up to 7 years of age. Pediatr Allergy Immunol. 2003; 14:448–452.

33. Bellou A, Kanny G, Fremont S, Moneret-Vautrin DA. Transfer of atopy following bone marrow transplantation. Ann Allergy Asthma Immunol. 1997; 78:513–516.

34. Byremo G, Rød G, Carlsen KH. Effect of climatic change in children with atopic eczema. Allergy. 2006; 61:1403–1410.

35. Vähävihu K, Ylianttila L, Salmelin R, Lamberg-Allardt C, Viljakainen H, Tuohimaa P, et al. Heliotherapy improves vitamin D balance and atopic dermatitis. Br J Dermatol. 2008; 158:1323–1328.

36. Chait I, Allkins V. Remission of life-long atopic dermatitis after hyposensitisation to house dust mite. Practitioner. 1985; 229:609. 612.

37. Leroy BP, Lachapelle JM, Somville MM, Jacquemin MG, Saint-Remy JM. Injection of allergen-antibody complexes is an effective treatment of atopic dermatitis. Dermatologica. 1991; 182:98–106.

38. Tuft L. Studies in atopic dermatitis. V. Problems in inhalant hyposensitization and results of treatment. J Allergy. 1960; 31:1–11.

39. Elias PM, Hatano Y, Williams ML. Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms. J Allergy Clin Immunol. 2008; 121:1337–1343.

40. Yu HS, Kang MJ, Jung YH, Kim HY, Seo JH, Kim YJ, et al. Mutations in the filaggrin are predisposing factor in korean children with atopic dermatitis. Allergy Asthma Immunol Res. 2013; 5:211–215.

41. Suárez-Fariñas M, Dhingra N, Gittler J, Shemer A, Cardinale I, de Guzman Strong C, et al. Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. J Allergy Clin Immunol. 2013; 132:361–370.

42. Tokura Y. Extrinsic and intrinsic types of atopic dermatitis. J Dermatol Sci. 2010; 58:1–7.

43. Flohr C, Johansson SG, Wahlgren CF, Williams H. How atopic is atopic dermatitis? J Allergy Clin Immunol. 2004; 114:150–158.

44. Oosting AJ, de Bruin-Weller MS, Terreehorst I, Tempels-Pavlica Z, Aalberse RC, de Monchy JG, et al. Effect of mattress encasings on atopic dermatitis outcome measures in a double-blind, placebo-controlled study: the Dutch mite avoidance study. J Allergy Clin Immunol. 2002; 110:500–506.

45. Tang TS, Bieber T, Williams HC. Does "autoreactivity" play a role in atopic dermatitis. J Allergy Clin Immunol. 2012; 129:1209–1215.

46. Gendelman SR, Lang DM. Specific immunotherapy in the treatment of atopic dermatitis: a systematic review using the GRADE system. Ann Allergy Asthma Immunol. 2013; 111:555–561.

47. Nouri-Aria KT. Foxp3 expressing regulatory T-cells in allergic disease. Adv Exp Med Biol. 2009; 665:180–194.

48. Miyara M, Wing K, Sakaguchi S. Therapeutic approaches to allergy and autoimmunity based on FoxP3+ regulatory T-cell activation and expansion. J Allergy Clin Immunol. 2009; 123:749–755.

49. Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol. 2011; 127:18–27.

50. Kim HJ, Kim YJ, Lee SH, Yu J, Jeong SK, Hong SJ. Effects of Lactobacillus rhamnosus on allergic march model by suppressing Th2, Th17, and TSLP responses via CD4(+) CD25(+)Foxp3(+) Tregs. Clin Immunol. 2014; 153:178–186.

51. Weiss ST. Bacterial components plus vitamin D: the ultimate solution to the asthma (autoimmune disease) epidemic? J Allergy Clin Immunol. 2011; 127:1128–1130.

52. Torii S, Torii A, Itoh K, Urisu A, Terada A, Fujisawa T, et al. Effects of oral administration of Lactobacillus acidophilus L-92 on the symptoms and serum markers of atopic dermatitis in children. Int Arch Allergy Immunol. 2011; 154:236–245.

53. Yang HJ, Min TK, Lee HW, Pyun BY. Efficacy of probiotic therapy on atopic dermatitis in children: a randomized, double-blind, placebo-controlled trial. Allergy Asthma Immunol Res. 2014; 6:208–215.

54. Sidbury R, Sullivan AF, Thadhani RI, Camargo CA Jr. Randomized controlled trial of vitamin D supplementation for winter-related atopic dermatitis in Boston: a pilot study. Br J Dermatol. 2008; 159:245–247.

55. Lee SA, Hong S, Kim HJ, Lee SH, Yum HY. Correlation between serum vitamin d level and the severity of atopic dermatitis associated with food sensitization. Allergy Asthma Immunol Res. 2013; 5:207–210.

56. Shoenfeld Y. The idiotypic network in autoimmunity: antibodies that bind antibodies that bind antibodies. Nat Med. 2004; 10:17–18.

57. Schuster SJ, Neelapu SS, Gause BL, Janik JE, Muggia FM, Gockerman JP, et al. Vaccination with patient-specific tumor-derived antigen in first remission improves diseasefree survival in follicular lymphoma. J Clin Oncol. 2011; 29:2787–2794.

58. Nahm DH, Cho SM, Kim ME, Kim YJ, Jeon SY. Autologous immunoglobulin therapy in patients with severe recalcitrant atopic dermatitis: a preliminary report. Allergy Asthma Immunol Res. 2014; 6:89–94.

59. Nahm DH, Kim ME, Cho SM. The effects of intramuscular injection of autologous immunoglobulin on clinical severity and serum IgE concentration in patients with atopic dermatitis. Dermatology. 2015; 231:145–151.